TP53 and neoplasm: In 2024, the Alcala team generated tumor organoids (PDTOs) derived from neuroendocrine tumor patients and used the Random Forest model to classify variations in RNA‐seq data, identifying key driver gene mutations (e.g., TP53, STK11).[231] Through the analysis of gene expression patterns, cellular composition, and batch‐to‐batch variation, RNA‐seq technology not only helped validate organoid maturation markers and cellular differentiation potential, but also provided data support for organoid standardization and reproducibility.